Caris Life Sciences, Inc. is 1.3x more valuable than VERACYTE, INC. by market capitalization ($5.08 B vs $3.78 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VCYT | CAI |
|---|---|---|
| Market cap | $3.78 B | $5.08 B |
| US-listed rank | #1633 | #1396 |
| Revenue (latest FY) | $517.14M | $812.03M |
| Net income (latest FY) | $66.40M | -$68.09M |
| Net margin | 12.8% | -8.4% |
| P/E (trailing FY) | 56.9 | - |
| SEC filings | 1,126 | 102 |
Caris Life Sciences, Inc. is 1.3x more valuable than VERACYTE, INC. by market capitalization ($5.08 B vs $3.78 B).
In their latest fiscal years, VERACYTE, INC. reported $517.14M in revenue while Caris Life Sciences, Inc. reported $812.03M.
Full pages: VERACYTE, INC. and Caris Life Sciences, Inc., or browse the full rankings.